P36544 (ACHA7_HUMAN) Homo sapiens (Human)
Neuronal acetylcholine receptor subunit alpha-7 UniProtKBInterProSTRINGInteractive Modelling
502 aa; Sequence (Fasta) ; (Isoform 2; Isoform 3);
1 identical sequence: Pan troglodytes: A0A2J8J8V6
It is possible new templates exist for this target since these models were created.
Available Structures
32 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| Alpha-7 nicotinic acetylcholine receptor bound to alpha-bungarotoxin in a resting state |
Heteromer P60616; | 5×NAG; 5×NAG; 5×NAG; 5×CA; | ||||
| Assess | ||||||
| Human alpha7 nicotinic receptor in complex with the E3 nanobody and nicotine |
Heteromer | 5×NAG; 10×NAG; 5×NCT; | ||||
| Assess | ||||||
| Human alpha7 nicotinic receptor in complex with the E3 nanobody |
Heteromer | 5×NAG; 10×NAG; | ||||
| Assess | ||||||
| human alpha7 nicotinic receptor in complex with the C4 nanobody |
Heteromer | 5×NAG; 10×NAG; | ||||
| Assess | ||||||
| human alpha7 nicotinic receptor in complex with the C4 nanobody under sub-saturating conditions |
Heteromer | 5×NAG; 10×NAG; | ||||
| Assess | ||||||
| human alpha7 nicotinic receptor in complex with the C4 nanobody and nicotine |
Heteromer | 5×NAG; 10×NAG; 5×NCT; | ||||
| Assess | ||||||
| human alpha 7 nicotinic acetylcholine receptor bound to EVP-6124 and PNU-120596 | homo-5-mer | 5×NAG; 5×NAG; 5×CLR; 5×I33; 5×I34; | ||||
| Assess | ||||||
| human alpha 7 nicotinic acetylcholine receptor bound to EVP-6124 | homo-5-mer | 5×NAG; 5×I33; 5×NAG; 5×CLR; | ||||
| Assess | ||||||
| human alpha 7 nicotinic acetylcholine receptor in apo-form | homo-5-mer | 5×NAG; 5×NAG; 5×CLR; | ||||
| Assess | ||||||
| Alpha7-nicotinic acetylcholine receptor time resolved resting state | homo-5-mer | 10×NAG; 5×NAG; 5×R16; 5×9Z9; 5×POV; | ||||
| Assess | ||||||
| Alpha7-nicotinic acetylcholine receptor time resolved bound to epibatidine and PNU-120596 asymmetri… | homo-5-mer | 5×NAG; 10×NAG; 5×EPJ; 5×I34; 3×CA; | ||||
| Assess | ||||||
| Alpha7-nicotinic acetylcholine receptor bound to GAT107 | homo-5-mer | 5×NAG; 5×NAG; 10×POV; 5×9Z9; 5×NAG; 5×YLI; | ||||
| Assess | ||||||
| Alpha7-nicotinic acetylcholine receptor time resolved bound to epibatidine and PNU-120596 asymmetri… | homo-5-mer | 5×NAG; 10×NAG; 5×EPJ; 5×I34; 3×CA; | ||||
| Assess | ||||||
| Alpha7-nicotinic acetylcholine receptor bound to epibatidine and (-)-TQS | homo-5-mer | 5×NAG; 5×NAG; 5×CA; 5×NAG; 10×POV; 5×9Z9; 5×EPJ; 5×YLR; | ||||
| Assess | ||||||
| Alpha7-nicotinic acetylcholine receptor bound to epibatidine and GAT107 | homo-5-mer | 5×NAG; 5×NAG; 5×CA; 5×NAG; 10×POV; 5×9Z9; 5×EPJ; 5×YLI; | ||||
| Assess | ||||||
| Alpha7-nicotinic acetylcholine receptor time resolved bound to epibatidine and PNU-120596 desensiti… | homo-5-mer | 5×NAG; 5×NAG; 5×CA; 5×NAG; 15×POV; 5×9Z9; 5×EPJ; 5×I34; | ||||
| Assess | ||||||
| Alpha7-nicotinic acetylcholine receptor bound to epibatidine and PNU-120596 | homo-5-mer | 5×NAG; 5×NAG; 5×CA; 5×NAG; 15×POV; 5×9Z9; 5×EPJ; 5×I34; | ||||
| Assess | ||||||
| Alpha7-nicotinic acetylcholine receptor bound to epibatidine and ivermectin | homo-5-mer | 5×NAG; 5×NAG; 5×CA; 5×NAG; 5×9Z9; 5×EPJ; 5×IVM; 5×POV; | ||||
| Assess | ||||||
| Alpha7-nicotinic acetylcholine receptor bound to epibatidine | homo-5-mer | 5×NAG; 5×NAG; 5×CA; 5×NAG; 15×POV; 5×9Z9; 5×EPJ; | ||||
| Assess | ||||||
| Alpha-7 nicotinic acetylcholine receptor bound to epibatidine and PNU-120596 in the activated state | homo-5-mer | 5×NAG; 10×NAG; 5×EPJ; 5×CA; | ||||
| Assess | ||||||
| Alpha-7 nicotinic acetylcholine receptor bound to epibatidine in a desensitized state | homo-5-mer | 5×NAG; 10×NAG; 5×EPJ; 5×CA; | ||||
| Assess | ||||||
| Alpha7-nicotinic acetylcholine receptor bound to epibatidine and NS-1738 | homo-5-mer | 5×NAG; 5×NAG; 5×XG3; 5×NAG; 5×EPJ; 5×9Z9; 5×POV; | ||||
| Assess | ||||||
| Structures of the Intracellular Domain and Transmembrane Domain of the Human alpha7 Nicotinic Acety… | homo-5-mer | |||||
| Assess | ||||||
| Alpha7 nicotinic acetylcholine receptor intracellular and transmembrane domains bound to ivermectin… | homo-5-mer | 5×IVM; | ||||
| Assess | ||||||
| alpha7-AChBP in complex with lobeline and fragment 5 | homo-5-mer | 10×NAG; 1×BMA; 1×MAN; 5×L0B; 5×OJD; 4×GOL; | ||||
| Assess | ||||||
| alpha7-AChBP in complex with lobeline and fragment 1 | homo-5-mer | 10×NAG; 10×42R; 5×L0B; 3×GOL; 1×BMA; 1×MAN; | ||||
| Assess | ||||||
| alpha7-AChBP in complex with lobeline and fragment 2 | homo-5-mer | 1×NAG; 4×NAG; 5×L0B; 5×GOL; 6×5VU; | ||||
| Assess | ||||||
| alpha7-AChBP in complex with lobeline and fragment 3 | homo-5-mer | 1×NAG; 4×NAG; 5×L0B; 5×GOL; 1×TLA; 1×FHV; | ||||
| Assess | ||||||
| alpha7-AChBP in complex with lobeline | homo-5-mer | 1×NAG; 4×NAG; 5×L0B; | ||||
| Assess | ||||||
| alpha7-AChBP in complex with lobeline and fragment 4 | homo-5-mer | 10×NAG; 5×L0B; 4×GOL; 5×9Z0; | ||||
| Assess | ||||||
| Crystal structure of the chimera of human 14-3-3 zeta and phosphorylated cytoplasmic loop fragment … | homo-2-mer | 4×EDO; 3×AZI; 1×BEZ; 1×PEG; | ||||
| Assess | ||||||
| NMR structures of the alpha7 nAChR transmembrane domain. | monomer | |||||
| Assess | ||||||
6 SWISS-MODEL models
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 7ekp.1.A | homo-5-mer | 0.71 | 5×I33; 4×CLR; | 100.00 | ||
| Assess | ||||||
| 7ekp.1.A | homo-5-mer | 0.71 | 5×I33; 4×CLR; | 100.00 | ||
| Assess | ||||||
| 7ekp.1.A | homo-5-mer | 0.71 | 5×I33; 4×CLR; | 100.00 | ||
| Assess | ||||||
| 7rpm.1.A | homo-5-mer | 0.57 | 98.50 | |||
| Assess | ||||||
| 7rpm.1.A | homo-5-mer | 0.57 | 98.50 | |||
| Assess | ||||||
| 7rpm.1.A | homo-5-mer | 0.57 | 98.50 | |||
| Assess | ||||||
3 SWISS-MODEL models built on isoform sequence
| Template | Isoform | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) |
|---|---|---|---|---|---|---|
| Isoform 2 | 7ekp.1.A | homo-5-mer | 0.72 | 5×I33; 4×CLR; | 100.00 | |
| Assess | ||||||
| Isoform 2 | 7rpm.1.A | homo-5-mer | 0.59 | 98.50 | ||
| Assess | ||||||
| Isoform 3 | 7ekp.1.A | homo-5-mer | 0.76 | 85.57 | ||
| Assess | ||||||